Copyright
©The Author(s) 2020.
World J Clin Oncol. Feb 24, 2020; 11(2): 53-73
Published online Feb 24, 2020. doi: 10.5306/wjco.v11.i2.53
Published online Feb 24, 2020. doi: 10.5306/wjco.v11.i2.53
Table 8 Summary of current objective response assessment criteria
Response assessment criteria | Year | Imaging modalities | Assessment type | Advantages | Disadvantages |
WHO | 1979 and 1981 | CT | Anatomic, size-based | First objective measurements of images of all lesions | Time-consuming procedure; Interobserver variability |
RECIST v1.0 | 2000 | CT, MRI | Anatomic, size-based | Easier than WHO; Measurement of "Target" and "Non-target" lesions; Less measurement errors | Only anatomic assessment |
RECIST v1.1 | 2009 | CT, MRI, PET | Anatomic, size-based | Easier than RECIST v1.0 Lymph nodes incorporated | Only anatomic assessment |
mRECIST | 2006 | CT, MRI | Anatomic, size-based | Simpler than RECIST v1.1 | Only anatomic assessment, not prospectively validated |
mRECIST for HCC | 2010 | CT, MRI | Anatomic and functional; Based on contrast enhancement | Measurement of a viable tumor. Appropriate for loco-regional therapies | Only for HCC |
EASL and qEASL | 2000 and 2012 | CT, MRI | Anatomic and functional; Based on contrast enhancement | qEASL is better than RECIST to predict OS; Measurement of a viable tumor | Only for HCC |
Choi criteria | 2007 | CT | Anatomic and functional; Based on tumor density | Validated for GIST, more precise than RECIST; Measurement of a viable tumor | Only for GIST |
Morphologic Response | 2009 | CT | Anatomic and functional; Based on morphologic changes | Appropriate for bevacizumab treatment | For CRC liver met., not prospectively validated |
irRC | 2009 | CT, MRI | Anatomic, size-based | For the treatment with immune-checkpoint inhibitors, capture of atypical response (pseudoprogression) | The variability of interpretation |
irRECIST | 2013 | CT, MRI | |||
iRECIST | 2017 | CT, MRI | |||
imRECIST | 2018 | CT, MRI | |||
EORTC PET PERCIST 1.0 iPERCIST | 1999, 2009, 2019 | PET | Metabolic | Detection of early metabolic changes | Limited resolution for tumors less than 0.4 cm. In NSCLC patients, retrospective |
MDA criteria | 2004 and 2010 | CT, MRI, XR, SS | Anatomic | A comprehensive evaluation of bone metastasis | Only for bone metastasis |
RANO | 2010 | MRI | Anatomic and functional; Based on contrast enhancement | Capture of pseudoprogression and pseudoresponse | Only for brain tumors |
- Citation: Aykan NF, Özatlı T. Objective response rate assessment in oncology: Current situation and future expectations. World J Clin Oncol 2020; 11(2): 53-73
- URL: https://www.wjgnet.com/2218-4333/full/v11/i2/53.htm
- DOI: https://dx.doi.org/10.5306/wjco.v11.i2.53